Quantx Risk Managed Multi-Asset Income Etf (delisted) (QXMI) News

Form 8-K - Current report

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

VOQUEZNA is now approved and available to treat the largest category of Gastroesophageal Reflux Disease...

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., May 28, 2024 (GLOBE NEWSWIRE) --  Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting

First oral presentation of Phase 3 data evaluating the investigational use of VOQUEZNA® in Non-Erosive Reflux...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Over 17,500 total prescriptions for VOQUEZNA® products have been dispensed, launch-to-date, a 361% increase...

Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024

Management to host conference call on Thursday, May 9, 2024, at 8:30 a.m. ET FLORHAM PARK, N.J., April 29...